Sam S. Chang MD, MBA
Medical School: Vanderbilt University School of Medicine
Residency: Vanderbilt University Medical Center
Fellowship: Memorial Sloan-Kettering Cancer Center
Clinical Interests: Prostate cancer, Prostatectomy, Bladder cancer, Kidney cancer, Urologic cancer
Dr. Chang, the Chief Surgical Officer at the Vanderbilt Ingram Cancer Center and the Urologic Oncology Division Chief, formerly chaired the American Joint Committee on GU Cancer Staging and the AUA/ASCO Guidelines on Bladder Cancer and was a member of the AUA Guidelines on Renal Cancer and the SUO Guidelines on Advanced Prostate Cancer. He is the past Chair of the American Board of Urology Examination Committee responsible for U.S. board certification and has been selected to serve as a Trustee of the American Board of Urology. His research in urologic oncology and clinical efforts have been recognized with national awards include the Distinguished Service Award of the SUO and the Gold Cystoscope Award and Hugh Hampton Young Award from the AUA.
Active Clinical Trials
Altor - QUILT-3.032
A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BHG) in Combination with ALT-803 in Patients with BCG Unresponsive High-Grade Non-Muscle Invasive Bladder Cancer – CA-ALT-803-01-16.
MDx Health – PRIORITY Study
Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study.